Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Conditions
Interventions
Tirzepatide
Placebo
Locations
65
United States
National Research Institute - Huntington Park
Huntington Park, California, United States
National Research Institute - Wilshire
Los Angeles, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
National Research Institute (NRI) - Santa Ana
Santa Ana, California, United States
Encompass Clinical Research
Spring Valley, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Start Date
March 29, 2021
Primary Completion Date
April 20, 2023
Completion Date
May 12, 2023
Last Updated
May 16, 2024
NCT07037459
NCT07351045
NCT07244458
NCT07508241
NCT05746039
NCT07395687
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions